Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Mr. Kazuto Koizumi, Managing Director and Head of Pharmaceuticals Group of Nippon Kayaku, commented as follows:
"Solasia is a specialty pharmaceutical company that excels in development of innovative medicines in the field of oncology in Japan and other Asian countries. Through the early launch of darinaparsin developed by Solasia, we expect to provide a new treatment option for PTCL, and contribute to patients and their family suffering from the disease, as well as to healthcare professionals."
Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:
"Nippon Kayaku is one of Japan's leading pharmaceutical companies with strengths in the field of oncology. We are very pleased to have this opportunity to deliver darinaparsin to nationwide medical institutions providing cancer treatment by utilizing Nippon Kayaku's extensive experience in oncology and strong sales network, and contribute to the treatment of PTCL."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
TOKYO -- Businesswire -- Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”).
Darinaparsin is a drug candidate under development by Solasia for relapsed or refractory peripheral T-cell lymphoma (PTCL). Solasia filed a new drug application with the Ministry of Health, Labour and Welfare in June 2021 and expects to launch after obtaining approval from the agency in 2022.
Mr. Kazuto Koizumi, Managing Director and Head of Pharmaceuticals Group of Nippon Kayaku, commented as follows: “Solasia is a specialty pharmaceutical company that excels in development of innovative medicines in the field of oncology in Japan and other Asian countries. Through the early launch of darinaparsin developed by Solasia, we expect to provide a new treatment option for PTCL, and contribute to patients and their family suffering from the disease, as well as to healthcare professionals.”
Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows: “Nippon Kayaku is one of Japan's leading pharmaceutical companies with strengths in the field of oncology. We are very pleased to have this opportunity to deliver darinaparsin to nationwide medical institutions providing cancer treatment by utilizing Nippon Kayaku’s extensive experience in oncology and strong sales network, and contribute to the treatment of PTCL.”
Based on this agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL, for which no standard treatment has been established to date.
About Nippon Kayaku Nippon Kayaku was founded in 1916 as the first industrial explosives manufacturer in Japan. We have developed products to meet the needs of the time by utilizing, combining and transforming our core technologies in the company’s main areas, explosives, dyes, pharmaceuticals and resins. Nippon Kayaku has contributed to realizing a sustainable society through its four businesses of Functional Chemicals, Pharmaceuticals, Safety Systems, and Agrochemicals. In the Pharmaceuticals Business, Nippon Kayaku specializes in anticancer drugs and other cancer-related products, handling a range of products from new drugs to biosimilars and generics. It strives to provide trustworthy information crucial for understanding anticancer drugs to medical institutions. Please visit the company website at https://www.nipponkayaku.co.jp/english/ for more information.
About Solasia Please visit the company website at https://solasia.co.jp/en/ for more information.
About darinaparsin (SP-02) Please visit at https://solasia.co.jp/en/pipeline/sp02.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005660/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Solasia Pharma K.K.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 농심, 2030년 유럽 매출 4배로 키운다 - 뉴스와이어
- 승우여행사, 봄꽃 테마 여행지로 순천 금둔사·광양 매화마을·구례 화엄사·고창 선운사 등 추천
- 현대자동차그룹, 2025년 ‘제로원 액셀러레이터’ 스타트업 모집 - 뉴스와이어
- 한국의길과문화-DMZ생태관광협회, 걷기여행 활성화를 위한 업무협약 체결 - 뉴스와이어
- 인피니언, 200mm SiC 웨이퍼 기술 기반의 SiC 제품 출시 - 뉴스와이어
- 아이야 ‘수상한 제삿날’ 낭독공연 개최 - 뉴스와이어
- 현대자동차그룹 정의선 회장, KIA 타이거즈 스프링캠프 깜짝 격려 방문 - 뉴스와이어
- 취향과 단계에 맞춰 배우는 전통예술 아카데미 ‘2025 전통공연예술문화학교’ 수강생 모집 - 뉴
- 도쿄관광한국사무소, 도쿄 여행을 더욱 편리하고 여유롭게 만들어주는 신규 호텔 3곳 소개 - 뉴
- GS25 ‘파스타모양초콜릿’ 단독 론칭 - 뉴스와이어